May 9, 2021

Knews

Your News Buddy

Pfizer predicts $ 26bn from the annual sale of Covid-19 | Pfizer

Drug manufacturer in the US Pfizer expects to make $ 26bn (£ 19bn) in revenue from the sale of its Covid-19 vaccine this year, with its remote sales earning more than half of the company’s annual revenue.

The vaccine, produced by Germany’s BioNTech, provided $ 3.5bn in international funding to Pfizer in the first three months of the year, and the company expected it to bring $ 15bn by the end of 2021.

Now the jab, priced at $ 39 on two units in the US and about $ 30 in the EU, makes 73% more than it claims. The company said taking it from jab would raise profits.

The new forecast is based on agreements signed until mid-April, to deliver 1.6bn worldwide worldwide this year. Pfizer is already offering US, UK, EU, Japan and Israel, in other markets, and is said to be close to signing a 100m doses agreement with Brazil. It also called for an agreement with Canada and Israel to provide a jab over this year.

The Pfizer Covid-19 vaccine is the first to be approved by health care providers, and it comes from a machine-generated RNA – a molecule that transmits genetic instructions from DNA to machine skin. This means it should be stored at high temperatures (-70C or -94F). In March, Pfizer and BioNTech began testing the vaccine in children from six months to 11 years of age.

The New York-based company expects to generate between $ 70.5bn and $ 72.5bn this year, while the coronavirus jab accounts for $ 26bn of that amount. Changes saved per session are estimated at $ 3.55 to $ 3.65. In the past, it predicts annual revenue of up to $ 61.4bn and changes in profits per share of $ 3.10 to $ 3.20.

Even after receiving the vaccine, Pfizer showed a lot of money, saying that its business did very well. It also reported a total revenue of $ 14.5bn in the first quarter.

The stimulus for funding from the Covid vaccine, called BNT162b2, was disrupted due to over-exposure to research and development. This increased by 20% in the first quarter of the year, largely due to the cost of vaccination and Covid-19 support. Pfizer divides the price by dividends vaccine similar to BioNTech.